We are honored that our SkinTE™ product, an Autologous Homologous Skin Construct (AHSC), will be featured in two podium presentations at the 38th Annual North American Burn Society Meeting that kicks off today. Hope to see you there. pte.co/SAFETY

NABS attendees, come hear Area Clinical Director Melodie Blakley present case studies highlighting success with SkinTE™, an autologous homologous skin construct (AHSC), to regenerate fully functional, full-thickness skin in traumatic and burn injuries pte.co/SAFETY

Today at NABS, Dr. William Abouhassan’s podium presentation highlighted the clinical use of our SkinTE™ product in over 20 patients, the majority of whom received SkinTE as a 1st-line treatment. Treatment included those with chronic and traumatic wounds. pte.co/SAFETY

While COVID-19 remains an evolving situation, we want to assure you that as an org, we're evolving with it. During this unique time, we've implemented response plans-with the care & safety of our community at the center. Learn more at polarityte.com

Learn about our Pilot Venous Leg Ulcer data by clicking this link woundsresearch.com/video/pilot-st…

We are pleased to join the 2020 WoundCon! #WoundConSpring2020 #woundcareconference

#transcript Dr. Ryan Mathis PolarityTE applying #regenerativemedicine for treating #diabeticfootulcers #complexwounds. #Autologous treatment gives wounds the ability to heal from the inside out. #tissueengineering #skin #woundcare #woundhealing #diabetic empoweredpatientradio.com/developing-aut…

PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers polarityte.com/news-media/pre…

SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial polarityte.com/news-media/pre…

Today is #WorldwidePressureInjuryPreventionDay! At PolarityTE, we are working to develop innovative therapies to help people living with #pressureinjuries. Check out these helpful resources from #NPIAP for both #healthcare professionals and #patients: npiap.com/page/2021WWPIPD

PolarityTE CSO Dr. Nik Sopko spoke with Health Radio Online about our investigational regenerative tissue technology to address #chronic wounds including #diabetic foot ulcers. Listen: bit.ly/3Ba02yL

#DiabeticFootUlcers are a significant risk to patients and can even be cause for amputation in severe cases. Learn how PolarityTE seeks to improve patient outcomes by harnessing natural regeneration processes to create functional tissue: bit.ly/3yWkXDb

CSO Dr. Nik Sopko sat down with @MrDannySullivan of Longevity Technology to discuss the ongoing Phase 3 trial of our investigational treatment for #DiabeticFootUlcers. Learn more: bit.ly/3UnN7iV

#DiabeticFootUlcers are a significant financial burden for patients, who are already faced with the costs of #diabetes itself. See how our investigational treatment has the potential to change the lives of patients: bit.ly/3yWkXDb

#ICYMI – This summer, PolarityTE CEO Richard Hague had the opportunity to speak with EmpoweredPatient on the #EmpoweredPatient Podcast about our investigational regenerative tissue technology and its potential to improve patient outcomes. Listen: bit.ly/3tgzvu9

#DYK – PolarityTE has a brand-new website! Check it out at polarityte.com and learn more about our mission to transform patient outcomes by developing personalized #autologous therapies.

Recurrence is common with #DiabeticFootUlcers, hence the need for a lasting, effective treatment. Learn how PolarityTE is harnessing regenerative cellular biology to develop new therapies for #DFU: bit.ly/3BxrLso

PolarityTE CSO Dr. Nik Sopko spoke with diaTribe about the current treatment landscape for #DiabeticFootUlcers, including SkinTE. Learn more: bit.ly/3VQjBmm

#DYK –SkinTE® is a novel and differentiated approach to #wound care that utilizes a patient’s own viable tissue. Learn more about our technology: bit.ly/3BxrLso

#ICYMI – CSO Dr. Nik Sopko sat down with Longevity Technology to discuss how PolarityTE is harnessing nature’s capacity for regeneration to treat patients with #DiabeticFootUlcers. Read: bit.ly/3UnN7iV